Houston John G

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 5

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 827,643

F6 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F7 · price: The broker sold shares of the Issuer's common stock for certain employees following the vesting of previously granted Restricted Stock Units, including the common stock reported on this Form 4 by the reporting person, at an average price of $77.4495.

F4 · balance_after: Includes an aggregate of 625 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 4

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 835,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · balance_after: Includes an aggregate of 625 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0000899243-21-009196 · doc4.xml · derivative · entry 6

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 219,500 shares

Expires 2031-02-25

F8 · derivative.exercise_date: This option award was granted on February 26, 2021. 1/4 of the shares underlying the award shall vest on February 26, 2022, with the remainder of the shares vesting in equal monthly installments following February 26, 2022 through February 26, 2025.

SEC source: 0000899243-21-007153 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,320

Underlying: Common Stock · 1,560 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007153 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007143 · doc4.xml · derivative · entry 6

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,880

Underlying: Common Stock · 44,000 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F7 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 5

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,200

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.13 to $80.49, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 4

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,800

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.13 to $80.06, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830,023

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.13 to $79.09, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 851,272

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.12 to $78.11, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 860,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 818,248

F2 · kind: The shares were acquired under the 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F4 · balance_after: Includes an aggregate of 625 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0001123292-20-001087 · edgar.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,687

Underlying: Common Stock · 10,687 shares

Expires 2030-09-09

F2 · derivative.exercise_date: The option vests on the earlier of June 11, 2021 and immediately prior to the 2021 Annual Meeting of Stockholders.

SEC source: 0001123292-20-001087 · edgar.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Underlying: Common Stock · 28,500 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on September 10, 2021.

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817,938

F2 · kind: The shares were acquired under the 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F3 · balance_after: Includes 315 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-20-021041 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,150

Underlying: Common Stock · 6,250 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.

SEC source: 0001209191-20-021041 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-020801 · doc4.xml · derivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,531

Underlying: Common Stock · 17,511 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001209191-20-020801 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 809,950

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of Arvinas Common Stock for certain Arvinas employees following the vesting of previously granted Restricted Stock Units, including the Common Stock reported on this Form 4 by the Reporting Person, at an average price of $37.61.

SEC source: 0001209191-20-020801 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 815,355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-20-014684 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,000

Underlying: Common Stock · 235,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

SEC source: 0001209191-19-061326 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,400

Underlying: Common Stock · 12,500 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.

SEC source: 0001209191-19-061326 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 797,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-19-019621 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,360

Underlying: Common Stock · 13,360 shares

Expires 2028-09-25

F1 · date: On September 26, 2018, the reporting person was granted an option to purchase 13,360 shares of common stock, which was reported on Form 4 filed September 28, 2018. The option vests upon achievement of a regulatory milestone for the Issuer's estrogen receptor program. On July 11, 2019, the compensation committee of the Issuer determined that the regulatory milestone was met, resulting in vesting of the option in full.

SEC source: 0000899243-19-006237 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,597

Underlying: Common Stock · 254,597 shares

Expires 2029-02-28

F3 · derivative.exercise_date: This option award was granted on March 1, 2019. 1/4 of the shares underlying the award shall vest on March 1, 2020, with the remainder of the shares vesting in equal monthly installments following March 1, 2020 through March 1, 2023.

SEC source: 0000899243-19-006237 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,042

Underlying: Common Stock · 70,042 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 1, 2020.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 1, 2020.

SEC source: 0000899243-19-001732 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,360

Underlying: Common Stock · 13,360 shares

Expires 2028-09-25

F1 · date: On September 26, 2018, the reporting person was granted an option to purchase 13,360 shares of common stock, which was reported on Form 4 filed September 28, 2018. The option vests upon achievement of a regulatory milestone for the Issuer's androgen receptor program. On January 18, 2019, the compensation committee of the Issuer determined that the regulatory milestone was met, resulting in vesting of the option in full.

SEC source: 0000899243-18-026075 · doc4.xml · derivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,484 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.exercise_date: On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · derivative.expiration_date: On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

SEC source: 0000899243-18-026075 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 785,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On October 1, 2018, the Series C Preferred Stock converted into Common Stock on a 3.25-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

SEC source: 0000899243-18-026075 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 772,860

F1 · shares: Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering.

SEC source: 0000899243-18-025553 · doc4.xml · derivative · entry 5

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,880

Underlying: Common Stock · 132,880 shares

Expires 2028-09-25

F5 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award shall vest on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-18-025553 · doc4.xml · derivative · entry 4

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,440

Underlying: Common Stock · 200,440 shares

Expires 2028-09-25

F4 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of September 15, 2018, with the remainder of the shares vesting in equal monthly installments following September 15, 2018 through September 15, 2021.

SEC source: 0000899243-18-025553 · doc4.xml · derivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,360

Underlying: Common Stock · 13,360 shares

Expires 2028-09-25

F3 · derivative.exercise_date: This option award was granted on September 26, 2018 and will vest upon achievement of a regulatory milestone for the Issuer's estrogen receptor program.

SEC source: 0000899243-18-025553 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,360

Underlying: Common Stock · 13,360 shares

Expires 2028-09-25

F2 · derivative.exercise_date: This option award was granted on September 26, 2018 and will vest upon achievement of a regulatory milestone for the Issuer's androgen receptor program.

SEC source: 0000899243-18-025553 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,900

Underlying: Common Stock · 106,900 shares

Expires 2028-09-25

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.